Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction (PEPCADNSTEMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01489449
Recruitment Status : Active, not recruiting
First Posted : December 9, 2011
Last Update Posted : November 4, 2020
Sponsor:
Information provided by (Responsible Party):
University Hospital, Saarland

Brief Summary:
The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R) Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI.

Condition or disease Intervention/treatment Phase
Coronary Heart Disease NSTEMI Device: Stent Device: SeQuent(R) Please coated balloon Phase 4

Detailed Description:
The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R) Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI. Primary efficacy endpoint will be MACE (cardiac mortality, reinfarction, and target lesion revascularization) after 9 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction
Actual Study Start Date : December 2012
Actual Primary Completion Date : June 23, 2018
Estimated Study Completion Date : June 23, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Placebo Comparator: Stent
Stent Implantation (DES or BMS), no further treatment
Device: Stent
bare metal stent implantation, any bare metal stent is allowed from different companies

Active Comparator: DCB
"DEBonly" strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection
Device: SeQuent(R) Please coated balloon
Angioplasty with Drug coated balloon (DCB)
Other Name: SeQuent(R) Please




Primary Outcome Measures :
  1. MACE [ Time Frame: 9 months ]
    MACE means the occurence of cardiac death, reinfarction, or target lesion revascularization


Secondary Outcome Measures :
  1. Stent thrombosis (ARC [ Time Frame: 9 months, 3 years, 5 years ]
  2. Mortality (cardiac and non-cardiac) [ Time Frame: 9 months, 3 years, 5 years ]
  3. Reinfarction [ Time Frame: 9 months, 3 years, 5 years ]
  4. target lesion revascularization [ Time Frame: 9 months, 3 years, 5 years ]
  5. target vessel revascularization [ Time Frame: 9 months, 3 years, 5 years ]
  6. any revascularization [ Time Frame: 9 months, 3 years, 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • NSTEMI with
  • Ischemic symptoms (angina pectoris) > 30 minutes
  • Last symptoms within 72 hours before randomization
  • Positive cardiac troponin T, I, or hs-Troponin above 99th percentile
  • age > 18 years
  • Identifiable culprit lesion without angiographic evidence of large thrombus with intended early PCI (treatment of up to two lesions allowed)

Exclusion Criteria:

  • Cardiogenic shock
  • ST-elevation myocardial infarction
  • No identifiable culprit lesion, Indication for acute bypass surgery
  • Comorbidity with limited life expectancy < 9-12 months
  • Contraindication for treatment with heparin, ASA and thienopyridines

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01489449


Locations
Layout table for location information
Germany
Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
Homburg/Saar, Saarland, Germany, 66421
Sponsors and Collaborators
University Hospital, Saarland
Investigators
Layout table for investigator information
Principal Investigator: Bruno Scheller, MD Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
Layout table for additonal information
Responsible Party: University Hospital, Saarland
ClinicalTrials.gov Identifier: NCT01489449    
Other Study ID Numbers: PEPCAD NSTEMI
First Posted: December 9, 2011    Key Record Dates
Last Update Posted: November 4, 2020
Last Verified: October 2020
Keywords provided by University Hospital, Saarland:
drug coated balloon
NSTEMI
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Non-ST Elevated Myocardial Infarction
Infarction
Ischemia
Pathologic Processes
Necrosis
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases